ArticleFrontiers in cardiovascular medicine2026
Association of advanced therapies for intermediate- to high-risk pulmonary embolism with improved right ventricular function on outpatient follow-up among survivors.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The impact of catheter-directed thrombolysis (CDT), catheter-directed embolectomy (CDE) and surgical pulmonary embolectomy (SPE) on long term RV function among patients with acute PE remains unclear. We investigated the association of receipt of advanced therapies with echocardiographic parameters of RV function at outpatient follow-up among survivors of acute PE. Methods: A retrospective cross-sectional study was performed on all patients with acute PE, who were managed in the Mount Sinai Health System (New York, NY) by PERT between January, 2021 and December, 2023, and had baseline & follow-up echocardiography performed. Non-parametric propensity score matching was performed in R using the Results: A total of 122 patients (70 male) were included with median age 64.4 years, median PESI score 86 points and ESC risk group intermediate-low (26 [21.3%]), intermediate-high (76 [62.3%]) and high (20 [16.4%]) risk respectively. CDE, CDT and SPE were performed in 21 (17.2%), 11 (9.0%) and 11 (9.0%) cases. In matched analyses, receipt of any advanced therapy (compared to anticoagulation alone) was associated with increased RVOT VTI (4.6 cm; Conclusion: Receipt of advanced therapies for acute PE was associated with statistically significant improvement in echocardiographic parameters of RV function at outpatient follow-up (median 26 weeks) among survivors of acute PE compared to systemic anticoagulation alone. Given the retrospective, non-randomized design, modest sample size, and use of surrogate endpoints, these findings should be considered hypothesis-generating and warrant confirmation in prospective studies incorporating clinical, functional, and patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.